E. Eisenstein, Y. Berkun, E. Ben-Chetrit
Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. firstname.lastname@example.org
2013 Vol.31, N°3 ,Suppl.77 - PI 0103, PF 0107
Free to view (click on article PDF icon to read the article)
The year 2012-2013 has been a fertile one in the area of FMF inquiry. Recent studies have led to further insight into the possible mechanisms whereby pyrin mutations might cause the auto-inflammatory phenotype that is characteristic of FMF. Evidence-based guidelines for diagnosis of FMF, including the role of genetic testing, have become available. Risks for colchicine resistance have been partially defined, and a randomised, controlled trial showing efficacy of an interleukin-1 antagonist for treatment of colchicine-resistant or intolerant FMF patients was reported. In this review, we summarise these and other salient findings from the recent FMF literature, and discuss their significance for the clinician.
PMID: 24064023 [PubMed]
Received: 29/07/2013 - Accepted : 02/08/2013 - In Press: 09/09/2013 - Published: 09/09/2013